1. Robert-Gangneux F, Dardé ML. Epidemiology of and Diagnostic Strategies for Toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264–96.
2. Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observations. Int J Parasitol. 2009;39(8):895–901.
3. Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27–40.
4. Alfredsson L, Olsson T. Lifestyle and Environmental Factors in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2019;9(4):a028944.
5. Sevimligul G, Polat ZA, Gokce SF. Toxoplasma gondii and multiple sclerosis: a population-based case-control sero-prevalence study, Central Anatolia, Turkey. Mult Scler Relat Disord. 2023;78:104871.
6. Shahra M, Keshavarz H, Sahraeian MA, et al. Associations between Toxoplasma gondii Infection and Multiple Sclerosis: A Case-Control Seroprevalence Study. Iran J Parasitol. 2023;18(2):165–71.
7. Tedford E, McConkey G. Neurophysiological Changes Induced by Chronic Toxoplasma gondii Infection. Pathogens. 2017;6(2):19.
8. Estato V, Stipursky J, Gomes F, et al. The Neurotropic Parasite Toxoplasma gondii Induces Sustained Neuroinflammation with Microvascular Dysfunction in Infected Mice. Am J Pathol. 2018;188(11):2674–87.
9. Papiri G, D’Andreamatteo G, Cacchiò G, et al. Multiple Sclerosis: Inflammatory and Neuroglial Aspects. Curr Issues Mol Biol. 2023;45(2):1443–70.
10. Cusick MF, Libbey JE, Fujinami RS. Molecular Mimicry as a Mechanism of Autoimmune Disease. Clin Rev Allergy Immunol. 2012;42(1):102–11.
11. Prandovszky E, Severance EG, Splan VW, Liu H, Xiao J, Yolken RH. Toxoplasma-induced behavior changes - is microbial dysbiosis the missing link? Front Cell Infect Microbiol. 2024; 14:1415079.
12. Nicoletti A, Cicero CE, Giuliano L, Todaro V, Lo Fermo S, Chisari C, et al. Toxoplasma gondii and multiple sclerosis: a population-based case–control study. Sci Rep. 2020;10(1):18855.
13. Cicero CE, Allibrio FE, Giuliano L, Luna J, Preux PM, Nicoletti A. Toxoplasma gondii and multiple sclerosis: A systematic review and meta-analysis. Eur J Neurol. 2021; 28(12):4251–4257.
14. Szepanowski F, Warnke C, Meyer zu Hörste G, Mausberg AK, Hartung HP, Kleinschnitz C, et al. Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. CNS Drugs. 2021;35(11):1173–88.
15. Ghahremani A, Ahmadabad HN, javadzadeh SM, shafiei R. The Potential Role of Toxoplasma gondii Infection in Multiple Sclerosis Development: A Seroepidemiological Study in North Khorasan Province, Iran. Acta Parasitol. 2025;70(1):32.
16. Wang Y, Guo L, Fan G, Han Y, Zhang Q, Ren L, et al. Impact of corticosteroids on initiation and half-year durability of humoral response in COVID-19 survivors. Chin Med J Pulm Crit Care Med. 2024;2(1):48–55.
17. Rahnama M, Asgari Q, Petramfar P, Tasa D, Hemati V, Solgi R. The Role of Toxoplasma gondii Infection Among Multiple Sclerosis Patient Compared to Ordinary People in South of Iran: A Case-Control Study. Mod Care J. 2020;17(3): e105090.
18. Sevimligul G, Polat ZA, Gokce SF. Toxoplasma gondii and multiple sclerosis: a population-based case-control sero-prevalence study, Central Anatolia, Turkey. Mult Scler Relat Disord. 2023;78:104871.
19. Wilson AG, Lapen DR, Mitchell GW, Provencher JF, Wilson S. Interaction of diet and habitat predicts Toxoplasma gondii infection rates in wild birds at a global scale. Global Ecol Biogeogr. 2020; 29: 1189–1198.
20. Shapiro K, Bahia-Oliveira L, Dixon B, et al. Environmental transmission of Toxoplasma gondii: Oocysts in water, soil and food. Food Waterborne Parasitol. 2019;15:e00049.
21. Ham DW, Kim SG, Seo SH, et al. Chronic Toxoplasma gondii Infection Alleviates Experimental Autoimmune Enc-ephalomyelitis by the Immune Regulation Inducing Reduction in IL-17A/Th17 Via Upregulation of SOCS3. Neurotherapeutics. 2021;18(1):430-447.
22. Jones JL, Dubey JP. Waterborne toxoplasmosis – Recent developments. Exp Parasitol. 2010;124(1):10–25.
23. Hussain MA, Stitt V, Szabo EA, Nelan B. Toxoplasma gondii in the Food Supply. Pathogens. 2017;6(2):21.
24. Boyce L. MSK Library Guides: COVID Impacts: Immune. https://libguides.mskcc.org/CovidImpacts/Immune
25. Yale Medicine. 2024. The Long COVID Puzzle: Autoimmunity, Inflammation, and Other Possible Causes. Available from: https://www.yalemedicine.org/news/the-long-covid-puzzle-autoimmunity-inflammation-and-other-possible-causes
26. National Institutes of Health (NIH). 2024. SARS-CoV-2 fragments may cause problems after infection. Available from: https://www.nih.gov/news-events/nih-research-matters/sars-cov-2-fragments-may-cause-problems-after-infection
27. Nath A, Berger JR. Complications of Immunosuppressive/Immunomodulatory Therapy in Neurological Diseases. Curr Treat Options Neurol. 2012;14(3):241–55.
28. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.
29. DeWolf S, Laracy JC, Perales MA, et al. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022;55(10):1779–98.
30. Koskderelioglu A, Afsar I, Pektas B, Gedizlioglu M. Is Toxoplasma gondii infection protective against multiple sclerosis risk? Mult Scler Relat Disord. 2017;15:7–10.
31. Cromar GL, Epp J, Popovic A, Gu Y, Ha V, Walters B, et al. Toxoplasma infection alters dopamine-sensitive behaviors and host gene expression patterns associated with neuropsychiatric disease. PLoS Negl Trop Dis. 2022;16(7):e0010600.
32. Pacheco R, Contreras F, Zouali M. The Dopaminergic System in Autoimmune Diseases. Front Immunol. 2014; 5:117.
33. Waubant E, Lucas R, Mowry E, et al. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol. 2019;6(9):1905–22.
34. Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. 2017;140(3):527–46.